Cyclophosphamide News and Research

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

20. November 2009 11:24

The debate on how to select patients who will respond best to costly drug treatments for aggressive breast cancer now favors fluorescence in situ hybridization (FISH) to measure the HER-2 receptor found in human breast tumors, according to a leading pathologist presenting at the Association for Molecular Pathology annual meeting. [More]

cb589363-95d8-48b5-b93d-447399d1a7e5|0|.0

Posted in: Device / Technology News | Women's Health News

Tags: Adjuvant Therapy, Breast Cancer, Cancer, Chemotherapy, Cyclophosphamide, DNA, Doxorubicin, Fluorouracil, Mammography, Oncology, Pathology

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

19. November 2009 03:13

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). [More]

7169822c-90e7-4db1-bb27-26e0162bbe54|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Cough, Cyclophosphamide, Headache, Hepatitis B, Leukemia, Lymphoma, MabThera, Methotrexate, Multiple Sclerosis, Nausea, Rheumatoid Arthritis, Rituximab, Virus

New radical approach to test chemo drugs for potential toxic effects

19. November 2009 02:25

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects. [More]

c84a42b1-b80f-4fe7-93c5-00d675c6b98b|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anemia, Bone, Bone Marrow, Cancer, Chemotherapy, Cyclophosphamide, Docetaxel, Doxorubicin

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

11. November 2009 03:43

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine. [More]

f9a26b2b-e4b5-4bd0-9640-1af3a9b6dbc7|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Adjuvant Therapy, Breast Cancer, Cancer, Capecitabine, Chemotherapy, Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Hospital, Metastasis, Oncology, Xeloda

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

6. November 2009 07:38

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. [More]

c33ab7fd-4a47-496c-ab34-49adcecd0d14|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Alopecia, Anemia, Arsenic, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Gleevec, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Testicular Cancer, Xeloda

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

29. October 2009 04:54

Despite a recent study finding that an increasing number of women who had cancer in one breast are opting to have the other breast removed, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology(TM) for Breast Cancer discourages prophylactic mastectomy in women except for those considered high risk. [More]

45ec829a-3831-44c7-b9f8-483dce258941|0|.0

Posted in: Women's Health News

Tags: Adjuvant Therapy, Biopsy, Breast Cancer, Cancer, Chemotherapy, Cyclophosphamide, Epirubicin, Fluorouracil, Genetics, Hospital, Lymphedema, Mastectomy, Oncology, Paclitaxel, Pfizer, Taxol

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

22. October 2009 05:22

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients. [More]

74b248a8-f0d4-4193-b507-b88acce24c57|1|5.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Anthracycline, Breast Cancer, Cancer, Catheter, Cell, Chemotherapy, Congestive Heart Failure, Cough, Cyclophosphamide, Doxorubicin, Heart Failure, Hodgkin's Lymphoma, Hospital, Leukemia, Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma, Oncology, Prescription Drug, Rituximab, Thrombocytopenia, Vincristine

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

22. October 2009 01:40

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma. [More]

f4f541c0-5bc7-444a-abff-37b6118c369f|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cell, Constipation, Cough, Cyclophosphamide, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Pneumonia, Rituximab, Thrombocytopenia, Vincristine, Vomiting

Rituxan's sBLA receives a Complete Response from the FDA

19. October 2009 05:04

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX. [More]

dbcf2e2c-47f1-42eb-8f11-d148823f81ed|0|.0

Posted in: Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cell, Chemotherapy, Cough, Cyclophosphamide, Doxorubicin, Headache, Hepatitis B, Immunology, Lymphoma, MabThera, Methotrexate, Nausea, Oncology, Rheumatoid Arthritis, Rheumatology, Rituximab, Vincristine, Virus

Rituxan drug effective for treating ANCA-associated vasculitis

19. October 2009 02:05

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. [More]

dfcc2ec2-5f02-4e54-bfdd-8356db2d6f5c|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Allergy, Arthritis, Cell, Cyclophosphamide, Fertility, Hodgkin's Lymphoma, Hospital, Infertility, Lymphoma, Neurology, Non-Hodgkin's Lymphoma, Nursing, Orthopedic, Rheumatoid Arthritis, Rheumatology, Vasculitis, Wegener's Granulomatosis

Recently approved Gleevec drug for cancer treatment

19. October 2009 02:00

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia. [More]

41777e73-0af9-4922-882e-4353bdb22432|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Cancer, Chemotherapy, Chronic Myeloid Leukemia, Cyclophosphamide, Gleevec, Hospital, Infertility, Leukemia, Myeloid Leukemia, Neurology, Nursing, Orthopedic, Rheumatology, Scleroderma

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

14. October 2009 09:16

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed. [More]

f334ff73-856d-4d23-b058-7564a6af3f67|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Alopecia, Anemia, Arsenic, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Xeloda

Genentech releases Phase III PRIMA study findings

17. September 2009 02:14

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan. [More]

dba38df9-3932-485e-b0ae-917e837bd21d|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cell, Chemotherapy, Cough, Cyclophosphamide, Doxorubicin, Follicular Lymphoma, Headache, Hepatitis B, Immunology, Lymphoma, MabThera, Methotrexate, Nausea, Neurology, Oncology, Rheumatoid Arthritis, Rituximab, Vincristine, Virus

FDA approves Supplemental New Drug Application for DOXIL

10. September 2009 23:28

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer. [More]

f5653125-cb96-4be9-80b5-a091077a3d46|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Alopecia, Anemia, Anorexia, Anthracycline, Back Pain, Bone, Bone Marrow, Breast Cancer, Cancer, Cardiomyopathy, Cardiovascular Disease, Chemotherapy, Congestive Heart Failure, Constipation, Cyclophosphamide, Diarrhea, Docetaxel, Doxorubicin, Dyspnea, Education, Headache, Heart Failure, Hypersensitivity, Immunology, Kaposi's Sarcoma, Liposome, Multiple Myeloma, Nausea, Nephrology, Neuralgia, Neuropathy, Neutropenia, New Drug Application, Nursing, Oncology, Ovarian Cancer, Pregnancy, Radiotherapy, Sepsis, Thrombocytopenia, Vomiting

Gene variation associated with resistance to chemotherapy drug in women with breast cancer

9. June 2009 15:25

Researchers have found links between an individual's genetics and their response to treatment with chemotherapy. The findings, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, show how a genetic variant, located in the SOD2 gene, may affect how a person responds to the chemotherapy drug cyclophosphamide. Cyclophosphamide is used in the treatment of breast and other cancers. [More]

6ea68feb-eb78-4645-a1a1-f39229b3f4ff|0|.0

Posted in: Medical Research News

Tags: Breast Cancer, Cancer, Chemotherapy, Cyclophosphamide, Fluorouracil, Genetics, Manganese

<< Previous posts

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Cyclophosphamide News and Research

FISH technology accurate in measuring the HER-2 receptor in human breast tumors

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

New radical approach to test chemo drugs for potential toxic effects

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

NCCN Guidelines for breast cancer does not recommend prophylactic mastectomy in women

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Rituxan's sBLA receives a Complete Response from the FDA

Rituxan drug effective for treating ANCA-associated vasculitis

Recently approved Gleevec drug for cancer treatment

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Genentech releases Phase III PRIMA study findings

FDA approves Supplemental New Drug Application for DOXIL

Gene variation associated with resistance to chemotherapy drug in women with breast cancer

Recent Articles

Free!

Recent Comments

Twitter

Information

Cyclophosphamide News and Research

Medical News Cloud

Recent Articles